These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 19236376

  • 1. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Br J Haematol; 2009 Apr; 145(2):245-54. PubMed ID: 19236376
    [Abstract] [Full Text] [Related]

  • 2. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Apr; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

  • 3. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Apr; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 4. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 5. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Jul; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Pagano L, Prossomariti L.
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [Abstract] [Full Text] [Related]

  • 8. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C.
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [Abstract] [Full Text] [Related]

  • 9. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 12. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Apr 10; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
    Calvaruso G, Vitrano A, Di Maggio R, Ballas S, Steinberg MH, Rigano P, Sacco M, Telfer P, Renda D, Barone R, Maggio A, Investigators of the Multicenter Randomized Clinical Trial of Deferiprone versus Deferoxamine in Sickle-Cell-Disease.
    Blood Cells Mol Dis; 2014 Dec 10; 53(4):265-71. PubMed ID: 24814618
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S, Zhang W, Huang L, Jiang H.
    PLoS One; 2013 Dec 10; 8(12):e82662. PubMed ID: 24376563
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K, Sivaramakrishnan G.
    Expert Rev Clin Pharmacol; 2018 Jun 10; 11(6):641-650. PubMed ID: 29727586
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 10; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, Tzouvara E, Bourantas KL.
    Hematol J; 2004 Nov 10; 5(6):475-9. PubMed ID: 15570288
    [Abstract] [Full Text] [Related]

  • 19. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K, Pyar K, Wonke B.
    Med J Malaysia; 2000 Dec 10; 55(4):493-7. PubMed ID: 11221163
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
    Gomber S, Saxena R, Madan N.
    Indian Pediatr; 2004 Jan 10; 41(1):21-7. PubMed ID: 14767084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.